TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04282538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: 4-week (5 days per week) active rTMS (90%rMT, M1, 10Hz for 10s, 50s interval, 20 trains)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: 4-week (5 days per week) sham rTMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: 4-week (5 days per week) active tDCS (2mA, DLPFC, 20 min)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 4-week (5 days per week) sham tDCS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking training
Description: 4-week (5 days per week) walking training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Walking training
Description: 4-week (5 days per week) walking training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking training
Description: 4-week (5 days per week) walking training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Walking training
Description: 4-week (5 days per week) walking training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognition training
Description: 4-week (5 days per week) cognition training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognition training
Description: 4-week (5 days per week) cognition training
Study: NCT04113343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: Remimazolam via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam via oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: Alcohol
Study: NCT01144663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix™
Description: 4- or 3-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix™
Description: 4- or 3-dose intramuscular injection
Study: NCT03548948

Intervention type: OTHER
Group type: OTHER
Intervention: Plant-based high non-heme iron diet
Description: A plant-based diet with high non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet.
Study: NCT01173224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
Study: NCT02577146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: renal and bladder ultrasound with ureteral jet assessment
Description: The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
Study: NCT04600245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaluation of CARTOSOUND-FAM software for accurate three-dimensional reconstruction of the left atrium in patients referred for atrial fibrillation ablation.
Description: One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaluation of CARTOSOUND-FAM software for accurate three-dimensional reconstruction of the left atrium in patients referred for atrial fibrillation ablation.
Description: One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used
Study: NCT00972673

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: Inhaled steroid
Study: NCT02690662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Description: recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
Study: NCT03734835

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hesperidin
Description: 1000 mg hesperidin as two capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hesperidin and flaxseed
Description: 1000 mg hesperidin as two capsules and 30 grams flaxseed

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flaxseed
Description: 30 grams flaxseed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no supplementation
Study: NCT03439202

Intervention type: OTHER
Group type: OTHER
Intervention: Hypoxia
Description: Subject will conduct low-intensity exercise on a bike in different hypoxic conditions.
Study: NCT00845650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIGIV 3.5 mg/kg
Description: AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gamunex 90 mg/kg
Description: Gamunex 90 mg/kg total IgG as a single intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIGIV 7.0 mg/kg
Description: AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gamunex 180 mg/kg
Description: Gamunex 180 mg/kg total IgG as a single intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIGIV 14.0 mg/kg
Description: AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gamunex 360 mg/kg
Description: Gamunex 360 mg/kg total IgG as a single intravenous infusion.
Study: NCT04445675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support for breastfeeding and the feeding of infants' with breast milk
Description: The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding.
Study: NCT04055714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the Eustachian tubes
Description: Use the Aera Balloon through the nose to dilate the Eustachian tubes
Study: NCT01811875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optivate 500IU
Study: NCT01914874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Study: NCT00810056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Cognitive, academic achievement, and mental health screening assessment and report.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment
Description: Cognitive, academic achievement, and mental health screening assessment and report.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF)
Description: Weekly therapeutic skill groups and mentoring over a 9-month period.
Study: NCT01012375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: 10 mg capsule, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: 80 mg capsule, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: 80 mg capsule, oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule, oral dose
Study: NCT01675635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyNorm Capsules
Description: dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morphine tablet
Description: dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.
Study: NCT01433575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: 10 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: 20 mg single oral dose
Study: NCT03699176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg, once daily, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, oral
Study: NCT00081159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orchiectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orchiectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: strontium chloride Sr
Description: 1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
Study: NCT03754777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: Preoperative care in both arms. Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~Surgery. General anesthesia with strict control of fluid therapy and hemodynamic changes during surgery. Appendectomy with the use of monopolar coagulation by experienced surgeons following appendix stump ligation by two Roeder knots.~Postoperative care. Antibiotics for 3-5 days for patients with complicated appendicitis (Gomez ≥ 3A). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 2, 6, 12 and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laparoscopic appendectomy
Description: Preoperative care in both arms. Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~Surgery. General anesthesia with strict control of fluid therapy and hemodynamic changes during surgery. Appendectomy with the use of monopolar coagulation by experienced surgeons following appendix stump ligation by two Roeder knots.~Postoperative care. Antibiotics for 3-5 days for patients with complicated appendicitis (Gomez ≥ 3A). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 2, 6, 12 and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery.
Study: NCT04627402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept and TA
Description: Intravitreous injection of Conbercept and TA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conbercept
Description: Intravitreous injection of Conbercept
Study: NCT02158546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study: NCT02446522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open vein harvesting
Description: Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
Study: NCT03325725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NewBreez LD intra-laryngeal implant
Description: NewBreez LD intra-laryngeal implantation
Study: NCT01763619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom Cervical Disc
Study: NCT03060135

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Check Your Drinking
Description: A anonymous brief survey designed to provide normative feedback of individual's drinking with the intent of motivating reductions in drinking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hello Sunday Morning
Description: Brief online intervention that allows Individual's reflect on their drinking reductions progress and goals.
Study: NCT03075527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
Study: NCT03116698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose DFD07 once daily
Description: Low dose DFD07 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose DFD07 once daily
Description: High dose DFD07 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose DFD07 twice daily
Description: High dose DFD07 twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo twice daily
Description: Placebo twice daily
Study: NCT01290380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404, DMXAA, DXAA
Description: ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
Study: NCT02301182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ADM X3-MoP Cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoC Cup
Study: NCT04002635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole ovulation induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Description: hormonal replacement therapy
Study: NCT04462094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.3 mg/kg at end-of-surgery
Description: Ketamine 0.3 mg/kg at end-of-surgery (intravenously)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine 0.3 mg/kg at end-of-surgery
Description: Ketamine 0.3 mg/kg at end-of-surgery (intravenously)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.3 mg/kg at anesthesia induction
Description: Ketamine 0.3 mg/kg at anesthesia induction (intravenously)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine 0.3 mg/kg at anesthesia induction
Description: Ketamine 0.3 mg/kg at anesthesia induction (intravenously)
Study: NCT00844753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atomoxetine
Description: atomoxetine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atomoxetine
Description: atomoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + parent management treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + parent management treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Management Training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent Management Training
Study: NCT03452696

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium supplement
Description: Calcium supplement for low contribution of elemental calcium in the daily diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium supplement
Description: Calcium supplement for low contribution of elemental calcium in the daily diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Calcium supplement for low contribution of elemental calcium in the daily diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Calcium supplement for low contribution of elemental calcium in the daily diet
Study: NCT02984527

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wet wipes
Description: intimate hygiene with disposable wet wipes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wet wipes
Description: intimate hygiene with disposable wet wipes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: water and soap
Description: Intimate hygiene with water and soap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: water and soap
Description: Intimate hygiene with water and soap
Study: NCT01505842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with Indigo-Carmine chromoendoscopy
Description: Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional white-light colonoscopy
Description: White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
Study: NCT03119909

Intervention type: OTHER
Group type: OTHER
Intervention: First session of fMRI: localization of the premotor areas of the medial frontal cortex
Description: Subjects should perform simple tasks to map the premotor areas of the medial frontal cortex. In this context, they will have to perform hand, tongue, ocular movements for about 20s. Additionally, as part of a control condition, they will need to perform eye fixation on a cross shown at the center of the screen for about 20s.

Intervention type: OTHER
Group type: OTHER
Intervention: Second fMRI session
Description: The subjects will position their left and right thumbs on response buttons. Each trial will begin with the appearance of one of 2 possible indexes. It will be an unknown abstract visual stimulus). After a variable delay of 0.5 to 6s (average = 2s), a blue or yellow circle will appear on the left or right of the screen.

Intervention type: OTHER
Group type: OTHER
Intervention: Third fMRI Session
Description: This session is identical to the second session but the subject will have to respond by performing saccadic ocular responses.

Intervention type: OTHER
Group type: OTHER
Intervention: Training fMRI session
Description: The training session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.

Intervention type: OTHER
Group type: OTHER
Intervention: Pilot behavioral study
Description: In a pilot study, 30 subjects will participate in a behavioral study (2 sessions of 2 hours each) aimed at establishing the learning characteristics of the different types of rare events unrelated to actions (visual and sensorimotors on the hand).

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI Study
Description: Each subject will participate in 2 fMRI sessions of about 2 hours each: a first session in which a first version of the task will be presented and a second session in which the second version of the task will be presented.
Study: NCT02300701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: According to manufacturer's instructions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo